Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
The company sticks with EZH2, despite others adding EZH1 inhibition.
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.